0001867096-24-000014.txt : 20240131 0001867096-24-000014.hdr.sgml : 20240131 20240131170432 ACCESSION NUMBER: 0001867096-24-000014 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Edick Paul R CENTRAL INDEX KEY: 0001531178 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40880 FILM NUMBER: 24583836 MAIL ADDRESS: STREET 1: C/O NEWLINK GENETICS CORP. STREET 2: 2503 SOUTH LOOP DR., SUITE 5100 CITY: AMES STATE: IA ZIP: 50010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc. CENTRAL INDEX KEY: 0001867096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 871082097 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 4 1 wk-form4_1706738662.xml FORM 4 X0508 4 2024-01-31 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0001531178 Edick Paul R C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 1 1 0 0 See Remarks 0 Common Stock 2024-01-31 4 A 0 1500000 0 A 3788064 D Common Stock 33430 I By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 Stock Appreciation Right 2.46 2024-01-31 4 A 0 500000 0 A 2026-03-03 Common Stock 500000 500000 D These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The award will vest in full on the two-year anniversary of the grant date. Upon exercise, the Stock Appreciation Right will be settled in cash. Chairman and Chief Executive Officer /s/ Beth Hecht, as Attorney-in-Fact 2024-01-31